Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201831 | 0.83 | BRD4 (0.49) | EGFRPTGS1PTGS2BRD4KAT2B | |
| SCHEMBL15059195 | 0.79 | AURKB (0.50) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15059636 | 0.76 | SMN1; SMN2 (0.54) | EGFRCDK8RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16201835 | 0.76 | PIK3CA (0.61) | — | |
| SCHEMBL8798667 | 0.73 | EGFR (0.61) | EGFRNPSR1RAB9AERBB2SMN1; SMN2 | |
| SCHEMBL16201834 | 0.72 | NPC1 (0.51) | EGFRNPSR1RAB9ANPC1 | |
| SCHEMBL20355107 | 0.70 | NPC1 (0.48) | EGFRNPSR1RAB9ANPC1NOD1 | |
| SCHEMBL4544782 | 0.68 | NFKB1 (0.54) | NPSR1RAB9ANPC1SMN1; SMN2NOD1 | |
| SCHEMBL6836432 | 0.68 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL2991673 | 0.68 | EGFR (1.00) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | UMPS, URB2, UROD | EGFR 2899/4885NOS3 1119/4885NOS1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.